RA Capital Reduces Vor Biopharma Stake by $10.2M, Now Owns 19.9%

summarizeSummary

RA Capital Management, a major institutional investor and director, reported selling approximately $10.2 million worth of Vor Biopharma shares, reducing its beneficial ownership to 19.9%.

check_boxKey Events

• Significant Share Sales by Institutional Investor

  RA Capital Healthcare Fund, L.P. sold a total of 620,133 shares of Vor Biopharma common stock between April 8 and April 10, 2026, for an aggregate value of approximately $10.2 million.

• Reduced Ownership Stake

  Following these transactions, RA Capital Management, L.P. and its affiliates beneficially own 12,554,642 shares, representing 19.9% of the company's outstanding common stock.

• Continued Disposition Pattern

  These sales continue a pattern of dispositions by RA Capital, as evidenced by recent Form 4 filings, suggesting a strategic reduction in their investment.

auto_awesomeAnalysis

RA Capital Management, a significant institutional investor with board representation through Peter Kolchinsky, has continued to reduce its stake in Vor Biopharma. This Schedule 13D/A reports sales of approximately $10.2 million in common stock between April 8 and April 10, 2026. These transactions, which overlap with a concurrently filed Form 4, follow previous dispositions by RA Capital, indicating a consistent reduction in their position. This continued selling by a major holder and director, especially against the backdrop of the company's recently reported $696.0 million net loss and negative equity for 2025, could signal a lack of confidence or a need for liquidity, potentially creating an overhang on the stock. Investors should monitor future filings for further changes in RA Capital's ownership.